The Role of Alloantibody in the Development of Cardiac Allograft Vasculopathy.

Alison J. Gareau,Bjorn Nashan,Timothy D. G. Lee

DOI: https://doi.org/10.1016/j.healun.2008.11.820

2009-01-01

Abstract:Allograft vasculopathy (AV) is the main pathological indicator of late cardiac graft rejection, resulting in graft loss at 10 years post-transplant. In AV a neointimal lesion forms, resulting in luminal occlusion and damage to the transplanted organ. AV is T-cell mediated, but the role that B cells and antibody play in AV development has been controversial. A widely quoted study reported that AV does not occur in the absence of B cells, whereas other studies have suggested that B cells and antibody play no role. No studies have been conducted in the presence of a clinically relevant immunosuppressant. We use cyclosporin A (CyA), a calcineurin inhibitor that is commonly used to prevent transplant rejection.